1. Durable Efficacy of Dolutegravir (DTG) Plus Lamivudine (3TC) in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI Studies. Issue 2 (February 2020) Authors: Cahn, P.; Madero, J. Sierra; Arribas, J.; Antinori, A.; Ortiz, R.; Clarke, A.; Hung, C.; Rockstroh, J.; Girard, P.; Sievers, J.; Man, C.; Urbaityte, R.; Underwood, M.; Tenorio, A.; Pappa, K.; Wynne, B.; Gartland, M.; Aboud, M.; van Wyk, J.; Smith, K. Journal: Journal of infection and public health Issue: Volume 13:Issue 2(2020) Page Start: 349 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Low Circulating Protein C Levels Are Associated with Lower Leg Ulcers in Patients with Diabetes. (2nd January 2013) Authors: Whitmont, K.; Fulcher, G.; Reid, I.; Xue, M.; McKelvey, K.; Xie, Y.; Aboud, M.; Ward, C.; Smith, M. M.; Cooper, A.; March, L.; Jackson, C. J. Other Names: Acosta Jorge Berlanga Academic Editor. Journal: BioMed research international Issue: Volume 2013(2013) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Superior Efficacy of Dolutegravir (DTG) Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Compared with lopinavir/ritonavir (LPV/r) Plus 2 NRTIs in Second-Line Treatment — 48-week Data from the DAWNING Study. Issue 1 (January 2019) Authors: Aboud, M.; Kaplan, R.; Lombaard, J.; Zhang, F.; Hidalgo, J.; Mamedova, E.; Losso, M.; Chetchotisakd, P.; Brites, C.; Sievers, J.; Brown, D.; Hopking, J.; Underwood, M.; Nascimento, M.; Gartland, M.; Smith, K.; Steinhart, C.; Gatell, J. Journal: Journal of infection and public health Issue: Volume 12:Issue 1(2019) Page Start: 107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Switching to DTG/3TC fixed-dose combination (FDC) Is non-inferior to continuing a TAF-based regimen in maintaining virologic suppression through 48 weeks (TANGO Study). Issue 2 (February 2020) Authors: Van Wyk, J.; Ajana, F.; Bisshop, F.; De Wit, S.; Osiyemi, Y.; Portilla, J.; Routy, J.; Wyen, C.; Ait-Khaled, M.; Nascimento, M.; Pappa, K.; Wang, R.; Wright, J.; Tenorio, A.; Wynne, B.; Aboud, M.; Gartland, M.; Smith, K.; El-Bahy, Y. Journal: Journal of infection and public health Issue: Volume 13:Issue 2(2020) Page Start: 349 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Two-drug regimen of dolutegravir plus lamivudine (DTG+3TC) is noninferior to dolutegravir plus tenofovir/emtricitabine (DTG+TDF/FTC) at 48 weeks in antiretroviral treatment-naive adults with HIV-1 infection: subgroup analyses in the GEMINI studies. Issue 1 (January 2019) Authors: Orkin, C.; Porteiro, N.; Berhe, M.; Dretler, R.; Viciana, P.; Tseng, Y.; Oprea, C.; Johnson, M.; Kulagin, V.; Man, C.; Sievers, J.; Currie, A.; Underwood, M.; Tenorio, A.; Pappa, K.; Wynne, B.; Aboud, M.; Smith, K.; Gartland, M.; Steinhart, C. Journal: Journal of infection and public health Issue: Volume 12:Issue 1(2019) Page Start: 147 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗